Pierre-Alexandre TEULIÉ is a visionary leader and expert in the orphan drug industry, currently serving as the CEO of ODDIFACT. With a proven track record of driving innovation and growth, Pierre-Alexandre is dedicated to advancing the field of orphan drugs through strategic partnerships and advocacy efforts.
With over two decades of experience at executive level, Pierre-Alexandre brings a unique blend of business acumen to his role. Personally affected by a rare condition, he is passionate about improving the lives of patients with rare diseases and is committed to developing novel therapies that address unmet medical needs.
As a speaker at the World Orphan Drug Congress 2026, Pierre-Alexandre will share his insights on effective strategies for navigating the complex landscape of orphan drug development and commercialization. His expertise in forming successful collaborations with key stakeholders, including patient advocacy groups, regulatory agencies, and industry partners, makes him a sought-after thought leader in the field.
Pierre-Alexandre's innovative approach to orphan drug development, combined with his dedication to patient-centric solutions, sets him apart as a leader in the industry. His vision for ODDIFACT is to continue driving forward the development of life-changing therapies for rare diseases, ultimately making a meaningful impact on the lives of patients worldwide.